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INTRODUCTION
Insulin dependent type 1 diabetes (T1D) is a chronic 
inflammatory disorder characterized by the autoim-
mune destruction of pancreatic β cells. The autoim-
mune reaction is a multistep process triggered by 
interactions  between  immune  cells  and  the  islets 
(reviewed in Kaminitz et al., 2007). Autoimmune 
insulitis  evolves  through  several  discrete  stages. 
Much evidence supports a crucial role for infiltrated 
immune cells in and around pancreatic islets early in 
the pathogenesis. Inflammation induces a program 
of changes within the tissue that promote immune 
surveillance  and  recognition.  In  the  process  of 
inflammatory insulitis, there is an accumulation of 
multiple cytotoxic mediators released by activated 
macrophages and T cells, other surrounding cells, 
as well as β cells themselves. Proinflammatory cyto-
kines (such as IL-1β, TNF-α, and IFN-γ) and the free 
radical nitric oxide (NO) play an important role in 
the initial destruction of β cells (Cnop et al., 2005). 
Functional impairment of β cells is induced shortly 
after exposure to cytokines, and an active process 
takes place at the β cell level, representing a race 
between  deleterious  and  protective  mechanisms. 
In  this  process  cytokine  production  from  target 
cells is specifically required for the transition from 
insulitis to diabetes (Flodstrom–Tullberg  et 
al., 2003). When the interaction between immune 
cells  and  islets  crosses  a  certain  point  of  inflam-
matory insulitis, it becomes difficult to control the 
pathogenic pathways and the autoimmune reaction 
culminates in β cell death and overt diabetes. So far, 
efforts  to  identify  immunotherapeutic  approaches 
in treatment of T1D have enjoyed limited success. 
Although  results  obtained  with  islet  transplanta-
tion are promising, interfering with the deleterious 
autoimmune  response  by  using  immunomodulat-
ing agents that can target multiple checkpoints or 
mechanisms within the inflammatory cascade still 
remains  a  conceivable  strategy  for  disease  treat-
ment. 
One of the cytokines involved in the inflamma-
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tory cascade during the progression of experimen-
tal autoimmune diabetes is macrophage migration 
inhibitory factor (MIF) (Cvetkovic et al., 2005; 
Stosic–Grujicic et al., 2008). This is an evolu-
tionarily conserved 12.5-kDa protein mediator with 
multiple functions in innate and acquired immunity 
(reviewed in bernhagen et al., 1998; Cvetkovic 
and  Stosic–Grujicic,  2006).  MIF  is  unique 
among cytokines because it exhibits certain endo-
crine properties and has enzymatic activity. MIF has 
been shown to regulate the expression of numerous 
genes  that  play  important  roles  in  cellular  stress 
responses, cell growth, and apoptosis. Upon secre-
tion, MIF acts as a typical inflammatory cytokine. 
As such, MIF is an attractive therapeutic target for 
the  treatment  of  immunoinflammatory  disorders, 
including diabetes. Thus, blocking MIF or its recep-
tor CD74 may provide new target-specific therapies. 
In the search for new immunomodulatory drugs, a 
novel  compound,  (S,R)-3-(4-hydroxyphenyl)-4,5-
dihydro-5-isoxazole acetic acid methyl ester or ISO-
1,  was  recently  synthesized  which  was  capable  of 
antagonizing MIF activity (Lubetsky et al., 2002). 
In  vivo  studies,  including  our  own,  demonstrated 
beneficial effects of ISO-1 in prevention and early 
treatment of a murine model of immune-mediated 
diabetes (Cvetkovic et al., 2005), experimental 
autoimmune  neuritis  (Nicoletti  et  al.,  2005), 
and  sepsis  (Al–Abed  et  al.,  2005).  As  we  have 
shown,  ISO-1  dampened  immunoinflammatory 
diabetogenic  processes  at  multiple  levels,  includ-
ing autoreactive lymphocyte propagation, adhesive 
cell-cell  interactions,  and  peripheral  secretion  of 
proinflammatory  mediators  (Cvetkovic  et  al., 
2005). However, realization of MIF’s potential as a 
drug target for T1D prevention also depends on an 
understanding of the MIF-governed events during 
the final stages of disease evolution within the target 
tissue.  Our  initial  observation  that  MIF  negation 
with ISO-1 protects mice from immunoinflamma-
tory diabetes by impairing peripheral immunologi-
cal circuits outside the pancreas (Cvetkovic et 
al., 2005) led to current studies aimed at elucidat-
ing MIF-mediated functional interactions between 
immune cell targets within the local environment. In 
the present study, we evaluated the direct effects of 
MIF inhibition by ISO-1 on the local inflammatory 
pathways in pancreatic islets under conditions that 
resemble  autoimmune  T1D.  We  show  that  ISO-1 
interferes with local cytokine-mediated NO produc-
tion (which otherwise leads to diabetes progression), 
thereby suggesting a potentially effective strategy for 
β cell protection.
MATeRIALS AND MeTHODS
Reagents and drugs
Streptozotocin (STZ, S-0130), collagenase type 
XI,  sulfanilamide,  naphthylethylenediamine  dihy-
drochloride,  3-[4,5-dimethylthiazole-2-yl]-2,5-
diphenyl-tetrazolium bromide (MTT), and fluores-
cein diacetate (FDA) were purchased from Sigma (St. 
Louis, MO). Percoll was from Pharmacia (Uppsala, 
Sweden).  RPMI-1640  medium  was  supplemented 
with 1 mM Hepes buffer, 5% fetal calf serum (FCS), 
1%  sodium  pyruvate,  and  2  mM  l-glutamine  (all 
from Flow Laboratories, Irvine, Gb); and penicil-
lin/streptomycin and 5x10-5 M 2-mercaptoethanol 
(Sigma).  (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-
5-isoxazole  acetic  acid  methyl  ester  (ISO-1)  was 
synthesized as described elsewhere (Lybetsky  et 
al., 2002). Recombinant cytokines IFN-γ, IL-1β and 
TNF-α were from Sigma.
Animals and treatment
Immunoinflammatory  (MLD-STZ)  diabetes 
induction and in vivo treatment with ISO-1 were 
performed in CbA/H mice exactly as described else-
where (Cvetkovic et al., 2005). In brief, STZ was 
injected i.p. at doses of 40 mg/kg daily for 5 consecu-
tive days. To evaluate the effect of ISO-1, the drug 
was administered as a continuous 14-day treatment 
by i.p. injection at a dose of 1 mg/mouse, starting 3 
days before the first STZ injection. The handling of 
animals and the study protocol were in accordance 
with international guidelines and approved by the 
local ethical committee. 
Cell cultures 
Resident  peritoneal  cells  (PC)  and  pancreases 
were collected from individual mice given MLD-STZ 
and treated with either ISO-1 or its vehicle, on day 15 
after the first STZ injection, as well as from normal, ISO-1 SUPPReSSeS DIAbeTeS 391
untreated mice. The pancreatic islets were isolated by 
collagenase digestion and Percoll gradient purifica-
tion as previously described (Stosic–Grujicic 
et al., 2001). Cell culture supernatants used for ex 
vivo detection of NO production by macrophages 
were obtained by co-culturing the cells for 5 days 
in 24-well Limbro culture plates in 1 ml of standard 
medium  (1x105 macrophages  and  100  islets/well). 
For ex vivo detection of cytokine secretion by pan-
creatic islets, islets were isolated from in vivo treated 
mice and cultured in medium in 24-well flat-bottom 
plates (100 pancreatic islets/well) for 48 h. 
Syngeneic  microvascular  endothelial  cells 
were prepared as described by Issecutz (1992). 
Syngeneic  pancreatic  fibroblasts  were  obtained 
according  to  Pechold  et  al.  (1997).  The  L929 
mouse fibrosarcoma cell line was from the european 
Collection of Animal Cell Cultures (Salisbury, UK). 
Rat  insulinoma  RINm5F  (RIN)  cells  and  mouse 
insulinoma MIN6 (MIN) cells were kindly donat-
ed by Dr. Karsten buschard (bartholin Instituttet, 
Copenhagen, Denmark). For the experiments, cells 
were  detached  by  trypsinization  and  incubated 
overnight in 96-well flat-bottom plates (6x104 L929 
cells/well, 4x104 fibroblasts and endothelial cells/well, 
8x104 RIN and MIN cells/well) or in 24-well flat-bot-
tom plates (100 pancreatic islets/well), then stimu-
lated with a cytokine combination (IFN-γ + IL-1β, 5 
μg/ml of each cytokine) in the presence or absence 
of various concentrations of ISO-1, as indicated in 
Results. Cell culture supernatants used for ex vivo and 
in vitro detection of cytokines or NO were collected 
after  48  h,  whereas  NO  production  in  pancreatic 
islet cell supernatants was measured after 5 days of 
cultivation. Subsequently, the viability of cultured β 
cells was determined in some experiments.
Assessment of cytokine and iNOS expression
by intracellular staining
Immunohistochemical  examination  of  pancre-
ases  was  performed  from  day  10  to  day  52  after 
MLD-STZ treatment. Pancreases were fixed in 10% 
buffered formalin and routinely embedded in wax. 
Deparaffinized  sections  were  boiled  in  a  750-W 
microwave in 0.01 M sodium citrate buffer (pH 6.0) 
to retrieve antigen. After blocking of endogenous 
peroxidase with 3% H2O2 in methanol, the slides 
were incubated for 1 h with the appropriate dilu-
tion of primary antibodies, followed by treatment 
with the extrAvidin rabbit peroxidase staining kit 
(Sigma)  according  to  the  manufacturer’s  instruc-
tions. Primary antibodies were as follows: rabbit anti-
TNF-α, anti-IL-1β, and anti-iNOS IgG were from 
Sigma; and rabbit anti-IL-18  was kindly donated by 
Dr. C. A. Dinarello, University of Colorado Health 
Science Center, Denver, CO. Diaminobenzidine was 
used as a color substrate.
The expression of iNOS in RIN cells was deter-
mined by cell-based eLISA, as previously described 
(Cvetkovic  et  al.,  2005).  briefly,  RIN  cells 
(8x104 cells/well) were allowed to adhere to poly-
L-lysine-precoated 96-well microplates. After fixa-
tion with 4% paraformaldehide and washing with 
0.1% Triton X-100 in PbS, endogenous peroxidase 
was quenched with 1% H2O2, and the reaction was 
blocked with 10% FCS. The cells were incubated for 
1 h with anti-iNOS IgG, and then with goat anti-rab-
bit Ig(H+L)-horseradish peroxidase. After washing, 
the cells were incubated for 15 min in the dark with 
O-phenylenediamine dihydrochloride (0.4 mg/ml), 
Na2HPO4
.2H2O (11.8 mg/ml), citric acid (7.3 mg/
ml), and 0.015% H2O2. The reaction was stopped 
with 3 N HCl, and the absorbance was measured in 
a microplate reader at 492 nm.  
Assessment of cytokines and NO production
in culture supernatants
Cell culture supernatant samples were analyzed 
in  duplicate  for  IL-12,  IL-1β,  TNF-α,  IFN-γ,  and 
IL-17 by eLISA using anti-mouse paired antibod-
ies (R&D System) according to the manufacturer’s 
instructions. 
As an indicator of NO formation, the concentra-
tion of the stable NO oxidation product nitrite in 
the culture supernatant was determined and aver-
aged from triplicate wells using the one-step Griess 
reagent  assay  (Stosic–Grujicic  et  al.,  2001) 
and compared with nitrite standards. 
Determination of β cell viability by MTT and FDA assay
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insulinoma cells was performed exactly as previous-
ly  described,  by  FDA  assay  (Stosic–Grujicic 
et al., 2007) and MTT assay (Miljkovic  et al., 
2005), respectively. In the FDA assay, the nonfluo-
rescent  molecule  FDA  is  hydrolyzed  inside  viable 
cells  to  fluorescein  by  the  intracellular  esterases, 
whereas hydrolysis is reduced in cells undergoing 
apoptosis. To discriminate living and dead cells at 
the end of incubation, MIN cells were pulsed with 
FDA for an additional 20 min and analyzed on a 
FACSCalibur  flow  cytometer  using  CellQuestPro 
software (becton Dickinson, Heidelberg, Germany). 
FDA-positive  cells  were  considered  viable.  In  the 
MTT assay, cell respiration, as an indicator of cell 
viability, was assessed by the mitochondrial-depen-
dent reduction of MTT to formazan. briefly, at the 
end  of  incubation,  RIN  cells  were  pulsed  for  an 
additional hour with 0.5 mg/ml MTT, the culture 
medium aspirated, and the cells lyzed in DMSO. The 
conversion of MTT to formazan was monitored on 
an automated microplate reader at 570 nm. 
Statistical analysis
Results are shown as mean values ± S.D. The 
statistical difference between groups was evaluated 
using an unpaired Student’s t test. A level of p < 0.05 
was considered to be significant. 
ReSULTS
Our  previous  study  showed  that  MIF  inhi-
bition  by  in  vivo  administration  of  ISO-1  pro-
duced  nearly  complete  protection  against  MLD-
STZ-induced clinical diabetes in susceptible mouse 
strains (Cvetkovic  et al., 2005). To evaluate the 
impact of in vivo treatment with ISO-1 on immu-
nopathological  changes  at  the  level  of  the  target 
tissue, in the present study we performed immu-
nohistochemical  analysis  of  pancreases  in  mice 
treated with MLD-STZ or MLD-STZ + ISO-1 and 
examined the local expression of proinflammatory 
mediators. Cytokines predominantly impair β cell 
function and cause β cell death via up-regulation of 
the inducible form of NO synthase (iNOS) expres-
sion and subsequent NO production (Chambers 
et al., 2008). We therefore measured the expression 
of  proinflammatory  cytokines,  as  well  as  iNOS. 
Fig.  1.  Immunohistochemical  profile  of  pro-inflammatory 
molecules of pancreatic islets. 
Sections from the pancreas are immunostained for IL-18 (A, 
B) IL-1β (C, D), TNF-α (E, F), and iNOS (G, H) as indicated in 
Materials and Methods. 
Photos are paired and represent the staining pattern of day-20 
control MLD-STZ-treated mice (left panels) vs. MLD-STZ plus 
ISO-1-treated mice (right panels). Typical sections are shown.
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Fig. 2. Pro-inflammatory cytokine protein levels in culture supernatants of isolated pancreatic islets. Pancreatic islets were isolated 
from day-15 control MLD-STZ-treated mice and from MLD-STZ plus ISO-1-treated mice. IL-12 (A), IL-1β (B), IFN-γ (C), and 
IL-17 (D) cytokine production was determined by ELISA in 48-h culture supernatants as indicated in Materials and Methods. Each 
column represents the mean value of five mice per each group; bars indicate SD. * P < 0.05 refers to corresponding MLD-STZ-treated 
control mice.
During MLD-STZ-induced diabetes, in control 
diabetic  mice  MNC  infiltrates  of  endocrine  pan-
creas were observed as early as day 10 of the disease, 
accompanied by scattered IL-18, IL-1β, TNF-α, and 
iNOS-positive  cell  staining  (not  shown).  Days  20 
and 30 of disease evolution were characterized by 
more  prominent  expression  of  the  proinflamma-
tory mediators tested (Fig. 1A-D) and islet necrosis. 
From this period up to the end of disease monitor-
ing (7 weeks), the destructive process progressed, 
resulting in islet atrophy. In contrast, administration 
of ISO-1 concomitantly with MLD-STZ markedly 
reduced the expression of IL-18, a cytokine respon-
sible for IFN-γ production, as well as that of IL-1β 
and TNF-α (Fig. 1C-F) in pancreatic islets of these 
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Fig. 3. Effect of in vivo treatment with ISO-1 on macrophage-
derived NO production. Peritoneal cells isolated from day-15 
control MLD-STZ-treated mice (STZ-PC) or MLD-STZ plus 
ISO-1-treated mice (ISO-STZ-PC) were cultured alone or in 
the presence of normal pancreatic islets (islets) for 7 days. Sub-
sequently, nitrite accumulation in cell culture supernatants was 
determined as indicated in Materials and Methods. Each col-
umn represents the mean ± SD for five animals per group. * P 
< 0.05 refers to control PC cultures without ISO-1.
also down-regulated by ISO-1 treatment (Fig. 1H). 
In  conformity  with  immunohistochemical  results, 
ex vivo analysis of proinflammatory cytokine secre-
tion confirmed a marked reduction of IL-12, IL-1β, 
IFN-γ, and IL-17 in supernatants of pancreatic islets 
isolated  from  MLD-STZ+ISO-1-treated  mice  (Fig. 
2). Thus, the drug treatment suppressed immune-
mediated destruction and preserved numerous islets 
from further autoimmune attack.
Total  cytokine  and  NO  production  of  the 
inflamed islets might originate from both β cells and 
associated cells of the pancreatic milieu, such as acti-
vated macrophages, capillary islet endothelial cells, 
and/or fibroblasts. To further dissect the effects of 
ISO-1 on local inflammatory pathways, we assessed 
the production of inflammatory mediators by both 
endocrine and nonendocrine cell preparations. Since 
macrophages  are  the  first  cells  to  accumulate  in 
islets during pathogenesis of T1D, we examined the 
influence of in vivo treatment with ISO-1 on mac-
rophage-derived  NO  production.  In  order  to  test 
macrophage activity, PC isolated from ISO-1- and/or 
MLD-STZ-treated mice just before the onset of dia-
betes (day 15 of diabetes induction) were co-cultured 
with normal pancreatic islets as a target tissue, and 
NO release was determined from nitrite accumula-
tion in the culture medium. The results clearly show 
(Fig. 3) that peritoneal macrophages isolated from 
MLD-STZ-treated mice produced high levels of NO, 
while macrophages from ISO-1-treated mice exhib-
ited impaired NO production. After co-culture with 
Fig. 4. In vitro effects of ISO-1 on NO production of the L929 
fibroblast cell line, primary fibroblasts, and primary endothe-
lial cells. (A) L929 fibroblasts (6x104 cells/well), (B) primary 
fibroblasts (4x104 cells/well), and (C) primary endothelial cells 
(4x104  cells/well)  were  cultured  overnight,  then  stimulated 
with 5 μg/ml of recombinant IL-1β + IFN-γ (Cyt) in the pres-
ence or absence of  ISO-1 (100 μg/ml) for the next 48 h. Con-
trol cells were cultured alone (medium) or in the presence of 
ISO-1. Nitrite accumulation in cell culture supernatants was 
subsequently determined as indicated in Materials and Meth-
ods. Each column represents the mean ± SD for triplicate cul-
tures. * P < 0.05 refers to control cultures without ISO-1.ISO-1 SUPPReSSeS DIAbeTeS 395
Fig. 5. In vitro effects of ISO-1 on the expression of iNOS and NO production of β cell lines and islet β cells. (A, C) RIN-m5F insuli-
noma cells (8x104 cells/well), (B) MIN6 insulinoma cells (8x104 cells/well), and (D) pancreatic islets (100 islets/well) were cultured 
overnight, then stimulated with 5 μg/ml of recombinant IL-1β + IFN-γ (Cyt) in the presence or absence of various concentrations 
of ISO-1 for the next 48 h (A, B, C) or for 5 days (D). Nitrite accumulation in cell culture supernatants (A, B, D) subsequently was 
determined as indicated in Materials and Methods. iNOS expression (C) was determined by cell-based ELISA as indicated in Ma-
terials and Methods. Each column represents the mean ± SD for triplicate cultures. * P < 0.05 refers to control cytokine-stimulated 
cultures without ISO-1.
pancreatic  islets,  MLD-STZ-derived  macrophages 
further increased their production of NO, whereas 
ISO-1-treated MLD-STZ-derived macrophages did 
not respond to islets and produced the same level of 
NO as when cultured alone. 
In order to see whether ISO-1 directly interferes 
with MIF-mediated stimulation of NO production 
in the pancreatic islets, NO production was deter-
mined in vitro where a combination of inflamma-
tory cytokines was used as a stimulus. We tested the 
direct in vitro effects of ISO-1 on production of NO 
by endothelial cells, fibroblasts, and β cells. To this 
end,  these  different  cell  preparations  were  stimu-
lated with a cytokine mixture of IL-1β and IFN-γ to 
mimic the inflammatory environment within islets 
attacked by activated mononuclear cells. As expect-
ed, exposure to a cytokine mixture of cell monolay-
ers of the L929 fibroblast cell line, primary fibro-
blasts,  and  primary  endothelial  cells  significantly 
increased mean nitrite accumulation above control 
levels  (Fig.  4A-C).  The  addition  of  ISO-1  slightly IvANA STOjANOvIć eT AL. 396
Fig. 6. In vitro effects of ISO-1 on the TNF-α production of β 
cell lines. (A) RIN-m5F and (B) MIN6 insulinoma cells (8x104 
cells/well) were cultured overnight, then stimulated with 5 μg/
ml of recombinant IL-1β + IFN-γ (Cyt) in the presence or ab-
sence of various concentrations of ISO-1 for the next 48 h. Se-
cretion of TNF-α was subsequently determined in cell culture 
supernatants by ELISA. Each column represents the mean ± 
SD for triplicate cultures. * P < 0.05 refers to control cytokine-
stimulated cultures without ISO-1.
inhibited this cytokine-induced NO production, but 
the differences between ISO-1-treated and nontreat-
ed cells reached statistical significance only in L929 
cells (Fig. 4A-C). We next examined the efficiency 
of ISO-1 in modulating NO production in β cells by 
using rat RIN and mouse MIN insulinoma cell lines 
as representatives. Incubation of RIN cells (Fig. 5A) 
and MIN cells (Fig. 5b) with IL-1β + IFN-γ resulted 
in significant formation of nitrite, while treatment 
with ISO-1 inhibited cytokine-induced NO release 
in both cell lines tested. To examine whether ISO-1 
inhibits NO release via suppression of iNOS, chang-
es of iNOS protein were investigated in RIN cells 
by  intracellular  staining  using  cell-based  eLISA. 
Cells  stimulated  with  cytokines  alone  markedly 
Fig. 7. In vitro effects of ISO-1 on survival of β cells. (A-C) 
MIN6 insulinoma cells (8x104 cells/well) and (D) RIN-m5F 
insulinoma cells  (8x104 cells/well)  were cultured overnight, 
then stimulated with 5 μg/ml of recombinant IL-1β + IFN-γ in 
the presence or absence of ISO-1 (100 μg/ml). The viability of 
cells was determined after 48 h by colorimetric FDA assay (A-
C) or MTT assay (D), as indicated in Materials and Methods. 
(A-C) Typical dot plots of flow cytometry analyses are shown. 
(D) Each column represents the mean ± SD for triplicate cul-
tures. * P < 0.05 refers to control cytokine-stimulated cultures 
without ISO-1.ISO-1 SUPPReSSeS DIAbeTeS 397
increased iNOS protein expression in comparison 
with unstimulated cells, whereas cells treated with 
cytokines and ISO-1 showed suppressed expression 
of  iNOS  (Fig.  5C).  Finally,  to  support  the  physi-
ological importance of the results obtained in the 
cell line studies and rule out the possibility that the 
observed effects were somehow specific for insulin-
oma cells, we assessed the influence of ISO-1 on NO 
production using freshly isolated mouse pancreatic 
islets. Although nitrite accumulation by mouse islets 
stimulated with IL-1β + IFN-γ was delayed in com-
parison with insulinoma cells, five-day incubation 
with a cytokine mixture achieved measurable NO 
production (Fig. 5D). Similar to results with insu-
linoma cells, islet treatment with ISO-1 diminished 
the effects of cytokines and resulted in the basal level 
of NO production (Fig. 5D). 
besides NO, cytokines produced by β cells could 
exert autocytotoxic effects. For this reason, we also 
measured the influence of ISO-1 on TNF-α secretion 
by insulinoma cells stimulated under the same con-
ditions as in the previous experiments. Compared to 
the control, the IL-1β + IFN-γ combination induced 
significant release of TNF-α in both RIN (Fig. 6A) 
and MIN cells (Fig. 6b). On the other hand, ISO-1 
affected in a dose-dependent way the induction of 
TNF-α in both cell lines (Fig. 6A and b).
Finally, we tested the direct effects of ISO-1 on 
β  cell  survival,  using  both  MIN  (Fig.  7A-C)  and 
RIN  cells  (Fig.  7D)  for  this  purpose.  In  addition 
to inducing high amounts of NO, treatment with 
the  combination  of  IL-1β  and  IFN-γ  was  appar-
ently toxic for RIN cells, as revealed by MTT assay, 
whereas ISO-1 significantly reduced cytokine-medi-
ated toxicity (Fig. 7D). Similarly, MIN cells in the 
presence  of  ISO-1  were  markedly  protected  from 
cytokine-induced death, to judge from FDA staining 
(Fig. 7C).   
DISCUSSION
In the current study, we found that treatment of 
pancreatic islets, insulinoma cells, fibroblasts, and 
endothelial  cells  in  vitro  with  the  pharmacologi-
cal MIF inhibitor ISO-1 down-regulated cytokine-
induced NO production, entailing a direct protective 
effect on β cells. Furthermore, the ability of ISO-1 to 
modulate in vitro the pattern of cytotoxic mediator 
generation  by  potential  residents  within  the  pan-
creas was reflected in vivo by down-regulation of 
macrophage NO-mediated cytotoxic activity and an 
extinguished inflammatory environment within the 
pancreas in treated mice. These results suggest that 
inhibition of the target tissue response substantially 
contributes to local regulation of the autoimmune 
process and identify MIF as a stimulator of local 
inflammatory  pathways  that  acts  in  a  permissive 
fashion and is able to control the set point of the 
final stage of disease evolution.
The tissue response to proinflammatory cyto-
kines can promote pathological tissue destruction 
in  autoimmune  diabetes  (Rabinovitch  and 
Suarez–Pinzon, 1998). These data are comple-
mented by the present results of immunohistochem-
istry showing in situ expression of proinflammatory 
molecules in the target tissue affected by the disease. 
evidence is now emerging which indicates that target 
cell cytokine responses are required specifically for 
transition from insulitis to diabetes (for review, see 
Hill et al., 2007). During evolution of the immune 
assault, the inflammatory environment acts bidirec-
tionally, further provoking self-perpetuating cycles. 
In support of complex network interactions, it has 
been shown that IL-18 is up-regulated in murine β 
cells in vitro upon exposure to IL-1β, TNF-α, and 
IFN-γ (Frigerio et al., 2002). Furthermore, IL-18 
is a potent inducer of IFN-γ, a cytokine which pro-
motes β cell death in combination with TNF-α and 
IL-1β  (Rabinovitch  and  Suarez–Pinzon, 
1998). In this report, we have described how MIF 
blockade  by  ISO-1  abrogates  target  cell  cytokine 
responses responsible for the transition from insuli-
tis to diabetes. Moreover, we demonstrated that both 
polarizing and downstream cytokines are reduced 
by ISO-1. This fits well with the already established 
position of MIF at the pinnacle of the inflammatory 
cascade, since MIF amplifies the generation of vari-
ous  other  proinflammatory  mediators  involved  in 
functional  suppression  and  destruction  of  β  cells. 
The  local  effect  of  ISO-1  could  be  attributed  to 
reduced activation of NO-producing inflammatory 
cells within the islets, as well as to prevention of IvANA STOjANOvIć eT AL. 398
the production of iNOS-inducing cytokines such as 
IL-1β, TNF-α, and IFN-γ. Consequently, decreased 
production of proinflammatory cytokines and NO 
generates a less deleterious environment in the islets. 
because  destructive  insulitis  is  closely  associated 
with Th1-type cytokine and NO production, it is 
apparent  that  ISO-1  suppresses  T1D  by  influenc-
ing the production of these mediators. Our present 
observations  of  reduced  pancreatic  production  of 
mediators of inflammation after ISO-1 treatment are 
in line with this. Interestingly, in the present study 
the resolution of immunoinflammatory diabetes by 
ISO-1 was associated with the suppression of Th17 
products, suggesting that MLD-STZ-induced diabe-
tes is a mixed Th1 and Th17 inflammatory environ-
ment. Thus, it seems that downstream effects of MIF 
include  the  production  not  only  of  IL-1,  TNF-α, 
and IFN-γ, but also of IL-17. This is in accordance 
with expanding diversity of effector T cell lineages 
in tissues, which has been linked to autoimmune 
inflammation (Weaver et al., 2007). Furthermore, 
we recently showed that IL-17 is an additional factor 
acting in concert with other inflammatory cytokines 
to induce nitric oxide synthase-dependent toxicity 
in mouse beta cells (Miljkovic  et al., 2005). In 
view of the detrimental effects of NO in immune-
mediated diabetes, of special interest is the reduced 
NO generation that we observed after ISO-1 treat-
ment in vitro.
It is well recognized that the nitrogen-based free 
radicals induced by proinflammatory cytokines are 
involved  in  the  pathological  processes  leading  to 
β cell dysfunction and death (Chambers  et al., 
2008). Moreover, in the presence of inflammatory 
cytokines, NO is a strong predictor of islet cell cyto-
toxicity (Thomas et al., 2002; Chambers et al., 
2008). It is reasonable to expect that the beneficial 
impact of ISO-1 treatment may result from modula-
tion of the iNOS pathway. Indeed, in this work we 
have shown that ISO-1 reduces iNOS expression and 
NO generation in the pancreatic islets, thus entailing 
a direct protective effect on β cells. In our experi-
mental model, the cellular sources of inflammatory 
mediators  may  be  both  endocrine  and  nonendo-
crine cells. In vivo, β cells are located in proximity to 
capillary islet endothelial cells and fibroblasts. Much 
evidence suggests that the main source of NO after 
islet stimulation by cytokines are the nonendocrine 
cells present in and around the islets, such as mac-
rophages,  endothelial  cells,  fibroblasts,  and  ductal 
cells (Cantor and Haskins, 2007; Steiner et 
al., 1997; Pavlovic et al., 1999). In addition to 
this, it has been shown that β cells themselves con-
tribute some of the cytokines and NO that provoke 
the immune reaction within the islets (Thomas et 
al., 2002). In the current study, we found that treat-
ment with ISO-1 influenced inflammatory cytokine 
and  NO  production  by  both  nonendocrine  cells 
(macrophages, endothelial cells, and fibroblasts) and 
pancreatic β cells. This is in line with our previous 
reports indicating that MIF is necessary for progres-
sion of autoimmune diabetes mellitus (Cvetkovic 
et al., 2005; Stosic–Grujicic et al., 2008) and 
further suggests that inhibition of MIF in the target 
organ (the pancreas) may promote the local coun-
ter-regulatory pathways that ensure the resolution of 
inflammation and protect against tissue damage.
Although  at  physiological  concentrations, 
endogenous free radicals are presumed to play roles 
in cell signaling (Droge, 2002), they clearly pos-
sess the capacity to behave in a destructive fashion. 
One of the unique features of pancreatic β cells is 
their  relatively  low  expression  and  activity  of  the 
enzymes involved in antioxidant defense, which ren-
ders β cells highly susceptible to NO/ROS-induced 
damage (Rabinovitch and Suarez–Pinzon, 
1998).  Although  it  is  well  established  that  high 
local NO production contributes to the induction 
of a death cascade in β cells, the role of NO in the 
mechanism responsible for the loss of β cell viability 
in response to cytokines is still debatable. Cytokines 
appear to kill β cells by NO-dependent necrosis that 
is caspase-independent (Chambers et al., 2008). 
On the other hand, NO is a mediator that combines 
with IL-1-β and IFN-γ to cause β cell death by apop-
tosis that is partly mediated by caspase-3 (Thomas 
et  al.,  2002).  Consistent  with  these  findings,  we 
recently demonstrated that systemic MIF deletion 
negatively  regulated  the  NO-induced  pathway  of 
apoptosis within the islets (Stosic–Grujicic  et 
al., 2008). In the present study, we provide further 
evidence  indicating  that  ISO-1  treatment  in  vitro ISO-1 SUPPReSSeS DIAbeTeS 399
results  in  suppression  of  local  cytokine-induced 
iNOS expression and high output NO production 
that could otherwise contribute to the impairment 
of β cell survival. Further studies on molecular inter-
actions may provide an improved understanding of 
the mechanisms underlying this inhibition.
Current studies suggest that strategies seeking to 
protect β cells from immune-mediated injury (i.e., 
attempts to prevent or reverse T1D) might benefit 
by the administration of ISO-1. Progressive β cell 
failure and loss is thought to represent a key event in 
the pathogenesis not only of T1D, but also of T2D. 
Although the signals and their pathways for β cell 
death in these two disorders are different (Cnop et 
al., 2005), NO may play an important role in both 
diseases. Given that in the present study we demon-
strated that treatment with ISO-1 can prevent local 
NO production, these results may imply a potential 
of ISO-1 for the treatment of T2D as well. 
Collectively,  our  work  points  to  MIF  as  an 
important  mediator  in  the  pathogenesis  of  T1D. 
MIF’s  position  within  the  inflammatory  cascade 
may be not only to control the magnitude of the 
systemic inflammatory response, but also to act in 
a permissive fashion to control the set point of the 
final stage of disease evolution leading to destructive 
insulitis and overt diabetes. It follows that inhibition 
of MIF’s action by ISO-1 may be a powerful phar-
macological strategy for the treatment of T1D and 
similar inflammatory and autoimmune diseases. We 
believe these studies provide a strong rationale for 
additional work seeking to identify the potential role 
of ISO-1 in the pathogenesis of T1D (and possibly 
T2D) and justify examination of the potential thera-
peutic benefits of ISO-1 administration for reversing 
and/or preventing these disorders.  
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недавﾭно  смо  показали  да  неуﾭтрализација 
инфламаторног  цитокина  MIF-а  фармаколо-
шким  инхибитором  ISO-1  негативﾭно  регуﾭлише 
имуﾭнски посредовﾭан дијабетес мишевﾭа. у овﾭом 
радуﾭ  испитивﾭали  смо  ефекте  неуﾭтрализације 
MIF-а помоћуﾭ ISO-1 на локалне инфламаторне ISO-1 SUPPReSSeS DIAbeTeS 401
пуﾭтевﾭе болести. In vivo третман мишевﾭа помоћуﾭ 
ISO-1  је  инхибирaо  експресијуﾭ  проинфлама-
торних  цитокина  и  индуﾭцибилне  синтазе  азот 
моноксида  уﾭ  острвﾭцима  панкреаса.  штавﾭише, 
ISO-1 је реметио in vitro продуﾭкцијуﾭ азот монок-
сида индуﾭковﾭануﾭ цитокинима уﾭ фибробластима, 
ћелијама ендотела, инсуﾭлиномaма и панкреасних 
острвﾭаца и тако сачуﾭвﾭао бета ћелије од оштећења 
изазвﾭаних азот моноксидом. овﾭи резуﾭлтати уﾭка-
зуﾭјуﾭ на регуﾭлаторни потенцијал ISO-1 на нивﾭоуﾭ 
циљﾭног ткивﾭа који штити циљﾭно ткивﾭо од  ауﾭто-
имуﾭног атака.